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Bone health of adult hemodialysis patients is related to vitamin K
status. This investigation of 68 hemodialysis patients (ages 33 to 91)
analyzed the association of biochemical indicators of vitamin K nutriture
and bone metabolism, and related both to past bone fracture history and
prospective bone fracture risk. Phylloquinonc concentrations were signif-
icantly lower in the 23 patients with previous fractures compared to those
without (0.93 vs. 1.50 nmol/liter, P < 0.003) and a smaller percentage of
their serum osteocalcin was carboxylated (48.8 vs. 53.6%, P < 0.03). The
41 patients who never had fractures had nearly three times higher
phylloquinone concentrations than the nine patients with fractures during
a four-year follow-up period (1.59 vs. 0.55 nmol/liter, P < 0.002) and more
carboxylated serum osteocalcin (55.2 vs. 42.0%, P < 0.01). None of the
patients with phylloquinone concentrations over 2.2 nmol/liter had ele-
vated intact parathyroid hormone (iPTH) concentrations, and only pa-
tients with less than I nmol/liter phylloquinone had severe hyperparathy-
roidism (iPTH>300 ng/liter). Our data thus indicate that suboptimal
vitamin K nutriture in hemodialysis patients is associated both with
increased bone fracture risk and with a high prevalence of hyperparathy-
roidism.
Vitamin K is an essential cofactor for the site-specific carbox-
ylation of osteocalcin and other bone matrix proteins [1]. Bio-
chemical indicators of reduced vitamin K status in otherwise
healthy adults are associated with increased urinary calcium losses
[2], reduced mineral density of the hip bone [3] and increased risk
of bone fracture [4]. Those who have already suffered a bone
fracture have been found to have lower vitamin K concentrations
in serum than age-matched controls [5—71. Long-term use of
vitamin K supplements normalized urinary calcium losses [8] and
maintained bone mineral density [9]. A year-long placebo-con-
trolled trial in hemodialysis patients showed a similarly favorable
effect of vitamin K supplements on bone density [10].
Less than optimal vitamin K status in otherwise healthy popu-
lations may be much more common than previously thought,
particularly in the elderly [2, 11, 12]. A recent investigation [13]
indicated that vitamin K status of middle-aged and elderly hemo-
dialysis patients is similarly precarious; one out of four hemodi-
alysis patients had a serum phylloquinone concentration that was
at least two SDS below the mean of healthy adults. The relevance
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of these findings was not clear, particularly in light of an earlier
report of higher than normal phylloquinone concentrations in a
majority of hemodialysis patients [14]. The aim of the present
study was, therefore, to determine how differences in bone health
of hemodialysis patients might be related to differences in vitamin
K nutriture. To this end we compared vitamin K status with the
history and four-year prospective risk of bone fractures.
Patients
Hemodialysis patients were recruited from three hemodialysis
centers in Berlin, Germany. All patients were clinically stable and
without acute infectious disease. They had been undergoing
hemodialysis on an outpatient basis for at least one month. No
patients were receiving vitamin K-antagonists at the time of blood
sampling.
All patients received 50,000 IU of vitamin D at the begin of
every quarter, each time in five oral doses spread over five days.
Additional calcitriol therapy was rarely used. Patients were rou-
tinely dialyzed against solutions containing 1.75 mmollliter cal-
cium.
Informed consent was obtained from all patients prior to the
study. The investigation was approved by the Institutional Review
Board of the Berlin Medical Association, Berlin, Germany.
Analytical methods
Bone fracture history. Information about previous fractures was
compiled from all available patient records both before and after
their diagnosis of renal disease. All patients had undergone
annual chest X-ray examinations from the start of hemodialysis
treatment. All recorded references to a bone fracture were
counted, whether these were obtained from dated hospital
records or were part of the patient's medical history, regardless of
cause, severity, location or age.
Blood samples. All patients observed an overnight fast before
blood for vitamin K and other analyses was obtained. The
preceding hemodialysis session always had been completed at
least thirty hours earlier. On the morning of the day of the study,
blood was drawn from an antecubital vein into plain and EDTA-
coated syringes for the preparation (within 2 hr) of serum or
plasma, respectively. All samples were protected from light during
collection, storage (— 20°C or lower) and analysis.
Biochemical analyses. Phylloquinone was analyzed by a multi-
stage procedure [151. The consecutive steps were extraction of
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Table 1. Indicators of vitamin K nutriture and bone metabolism in hemodialysis patients with a history of bone fractures at the time of recruitment
compared to those who did not have fractures until then
Fractures (N) No fractures (N) P
Age years 67.3 2.5 (23) 62.3 1.8 (45) <0.15
Years on hemodialysis 5.5 0.9 (23) 3.5 0.4 (45) <0.08
Phylloquinone nrnol/liter 0.93 0.25 (23) 1.50 0.20 (45) <0.003
Hydroxylapatite-binding osteocalcin % 48.8 2.2 (19) 53.6 1.6 (39) <0.03
Total osteocalcin 26.0 6.4 (19) 23.8 3.6 (39) NS
Intact parathyroid hormone ng/liter 228 64 (20) 165 50 (36) NS
Data are means and standard errors of the mean (sEM). The number of patients for which data are available is given in parentheses (NS indicates
P < 0.25).
Table 2. Indicators of vitamin K nutriture and bone metabolism in hemodialysis patients who suffered bone fractures after recruitment compared
to those who never had fractures
Fractures (N) No fractures (N) P
Age years 66.0 4.5 (9) 61.7 1.8 (41) NS
Years of hemodialysis 6.7 0.8 (9) 3.4 0.5 (41) <0.14
Phylloquinone nmol/liter 0.55 0.08 (9) 1.59 0.21 (41) <0.002
Hydroxylapatite-binding osteocalcin % 42.0 2.9 (8) 55.2 1.6 (35) <0.01
Total osteocalcin 34.0 6.7 (8) 23.4 4.0 (35) <0.15
Intact parathyroid hormone nglliter 180 66 (7) 160 47 (36) NS
Data are means and standard errors of the mean. The number of patients for which data are available is given in parentheses. Differences between
the groups were tested by Student's f-test (NS indicates P > 0.25).
lipophils from serum, purification by sorbent extraction and
normal-phase high-performance liquid chromatography (HPLC),
final separation by reversed-phase HPLC, and measurement of
the vitamin by dual-electrode electrochemical detection in the
redox-mode. Menaquinone-6 was used as an internal standard to
correct for losses. All measurements were carried out at least in
duplicate and the means of the results were used for data analysis.
Interassay variation (variation coefficient) was 11%. Undercar-
boxylated osteocalcin was separated from the carboxylated form
by incubating serum with hydroxylapatite [161. Osteocalcin was
measured in untreated serum and in hydroxylapatite-treated
serum by radioimmunoassay (OSCAtest Osteocalcin, Henning,
Berlin, Germany). Interassay variation for the measurement of
the undercarboxylated osteocalcin fraction was 16%. The concen-
tration of intact parathyroid hormone (iPTH) was measured with
a non-radioactive immunoassay (LIAmat iPTH, Byk-Sangtec,
Dietzenbach, Germany) with an interassay variation of 8%.
Statistics
Group differences were tested with the Kolmogorov-Smirnov
two-sample test for continuous variables and with Chi-square
statistics for fracture history. All calculations were carried out
with a statistical software package (Statgraphics 2.4, SCSC) on a
personal computer.
Results
Bone fracture history
A review of all available X-ray records and patient charts
showed that 23 of the 68 patients had suffered one or more
documented fractures prior to recruitment. In most cases (16 of
23) some or all of the fractures had occurred before hemodialysis
had become necessary. During the four years following recruit-
ment nine patients suffered new fractures; five of these had had
fractures previously.
Indicators of vitamin K nutriture
Serum phylloquinone concentrations varied widely in these
patients, ranging from 0.14 to 5.0 nmol/liter with a mean of 1.33
nmol/liter. Concentrations were not significantly related to gender
or age. Mean serum phylloquinone concentration (Table 1) was
38% lower in patients with a history of bone fractures at the time
of recruitment than in those without (0.93 vs. 1.50 nmol/liter, P <
0.003). There was an almost threefold difference (Table 2) in
phylloquinone concentrations of the nine patients who had bone
fractures during four years following recruitment and the 41
patients who never had a fracture (0.55 vs. 1.59 nmol/liter, P <
0.002).
The proportion of serum osteocalcin that binds to hydroxylapa-
tite in vitro, as a measure of the completeness of vitamin K-
dependent y-carboxylation of osteocalcin in bone [16], was as-
sayed in 58 of the patients. Measurements were not carried out for
the other 10 patients, because serum samples had been collected
inappropriately or not at all. The proportion of hydroxylapatite-
binding osteocalcin (HBC) was 9% lower in patients with frac-
tures prior to recruitment than in those who had not had a
fracture until then (48.8 vs. 53.6%, P < 0.03). HBC also was
significantly lower in the patients who later had fractures com-
pared to those who never had fractures. No statistically significant
effects of fracture history or prospective bone fracture risk on
serum osteocalcin concentrations were observed.
The percentage of hydroxylapatite-binding osteocalcin was cor-
related with phylloquinone concentration (r = 0.28, P < 0.05). No
statistically significant relationships were found between serum
phylloquinone concentrations and the concentrations of hydroxyl-
apatite-binding or non-binding osteocalcin.
Indicators of bone metabolism
Total osteocalcin concentrations in serum, an indicator of
osteoblast activity, did not differ significantly between patients
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with and without previous bone fractures. All patients had con-
centrations above the normal reference limits with values ranging
from 2.5 to 120 Lg/liter. Thirty-one of the 63 patients for whom
results were available had elevated plasma concentrations (> 60
ng/liter) of intact parathyroid hormone (iPTH), which is known to
increase serum osteocalcin concentrations [171. iPTH concentra-
tions tended to be higher in patients who had had previous
fractures than in those who had never had fractures, but the
difference was not statistically significant (Table 1). The same
pattern and absence of statistical significance of the difference was
observed in respect to prospective bone fracture risk (Table 2).
Plasma iPTH concentrations were related to serum phylloqui-
none concentrations (Fig. 1). A statistically significant correlation
was obtained after logarithmic transformation of both parameters
(r =
—0.45, P < 0.01). None of the ten patients with serum
phylloquinone concentrations over 2.2 nmollliter had an elevated
plasma iPTH, but 45% of patients with phylloquinone concentra-
tions between 1.0 and 2.2 nmol/liter had elevated iPTH concen-
trations, and 71% of patients with phylloquinone concentrations
below 1 nmol!liter. Only patients with a serum phylloquinone
concentration of less than 1 nmol/liter had iPTH concentrations in
excess of 300 ng/liter. Among the patients for whom iPTH values
were available 13 had fractures after starting hemodialysis; all but
one of these presented evidence of both suboptimal vitamin K
status and hyperparathyroidism (P < 0.02). Vitamin K-replete
patients, in contrast, appeared to have escaped both hyperpara-
thyroidism and bone fracture during hemodialysis treatment.
Discussion
Chronic renal failure causes severe disturbances of bone min-
eral metabolism that are not completely corrected by hemodialysis
treatment. Phosphate retention and impaired synthesis of 1,25-
dihydroxyvitamin D are common problems that are thought to
excessively stimulate parathyroid hormone secretion and which
may cause the accelerated loss of bone minerals. This study was
undertaken to determine whether poor vitamin K status might
contribute to the pathogenesis of renal osteodystrophy. From this
investigation two major findings emerged: Vitamin K status was
poorer in patients with fractures than in those without; and
hyperparathyroidism was most severe in patients with poor vita-
min K status.
The mechanism by which vitamin K might protect against bone
fracture is not known. While it is known that vitamin K is needed
for the synthesis of mature osteocalcin, matrix Gla protein and
protein S in bone, the specific function of these vitamin K-
dependent proteins is still obscure. The finding that only patients
with low phylloquinone concentrations had severely elevated
iPTH concentrations was unexpected. The close relationship
between vitamin K and iPTH concentrations may suggest that a
vitamin K-dependent process is important for the regulation of
parathyroid hormone. This could involve a calcium-binding pro-
—i—-- tein that is both vitamin K and vitamin D dependent, as is the case
5 6 with osteocalcin in bone.
Serum phylloquinone concentrations have previously been
found to be strongly dependent on apolipoprotein E genotype [13,
18]. Since this genetic trait is constant throughout life, current
phylloquinone concentrations may be indicative of past concen-
trations. This would explain how a slowly evolving event like bone
fracture can be linked to a parameter as volatile as vitamin K
concentration in serum.
The preventive and therapeutic potential of maintaining opti-
mal vitamin K status may be considerable. Patients with serum
phylloquinone concentrations of 1.2 nmol/liter or less had suffered
bone fractures at a rate of more than 6%/year during hemodialysis
treatment whereas none of the others had fractures. More than
half of the hemodialysis patients at our centers (and probably
elsewhere) had serum phylloquinone concentrations below this
threshold and might benefit from supplemental vitamin K. Pre-
liminary results from a placebo-controlled 12-month intervention
trial in hemodialysis patients [10] indicate that vitamin K supple-
mentation helps to conserve bone mineral mass and may thereby
decrease bone fracture risk. Apart from its effect on bone, we are
currently investigating whether vitamin K can decrease elevated
iPTH concentrations and thereby alleviate one of the most
obstinate problems in the treatment of end-stage renal failure.
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